From Memorial Sloan Kettering Cancer Center; The University of Texas MD Anderson Cancer Center; Huntsman Cancer Institute at the University of Utah; Dana-Farber/Brigham and Women's Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Mayo Clinic Cancer Center; UC San Diego Moores Cancer Center; Moffitt Cancer Center; Stanford Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; University of Colorado Cancer Center; City of Hope Comprehensive Cancer Center; Roswell Park Cancer Institute;University of Washington/Seattle Cancer Care Alliance; Massachusetts General Hospital Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fox Chase Cancer Center; Duke Cancer Institute; University of Michigan Comprehensive Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.
J Natl Compr Canc Netw. 2015 Feb;13(2):151-9. doi: 10.6004/jnccn.2015.0022.
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These NCCN Guidelines Insights highlight the recent updates/changes in these guidelines, and updates include axitinib as first-line treatment option for patients with clear cell renal carcinoma, new data to support pazopanib as subsequent therapy for patients with clear cell carcinoma after first-line treatment with another tyrosine kinase inhibitor, and guidelines for follow-up of patients with renal cell carcinoma.
NCCN 肾癌指南为透明细胞和非透明细胞肾细胞癌患者的临床管理提供了多学科建议。这些 NCCN 指南洞察强调了这些指南的最新更新/变化，更新包括阿昔替尼作为透明细胞肾细胞癌患者的一线治疗选择，新数据支持帕唑帕尼作为一线治疗另一种酪氨酸激酶抑制剂后透明细胞癌患者的后续治疗，以及肾细胞癌患者的随访指南。
